Purpose
To describe the incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage 1 seminoma (S1S) testicular cancer (TC) treated with a risk-adapted strategy.
Methods
A ...retrospective analysis from 2000 to 2020 was conducted. Active surveillance (AS), carboplatin one cycle, and carboplatin two cycles were offered according to risk factors. Cumulative incidences and relapse-free survival (RFS) were estimated.
Results
Of the 145 patients, 8 (5.4%) were excluded due to bilateral TC or hypogonadism at diagnosis. Median follow-up time was 8.2 years. Eighty-four, 30, and 33 patients were treated with AS, carboplatin one cycle, and carboplatin two cycles, respectively. In the overall population, the 5-year and 10-year cumulative incidences were 1.6% and 5.3% for hypogonadism; 2.0% and 8.6% for hypertension; and 12.4% and 25.1% for dyslipidaemia. No statistically significant differences were found in the incidences among the three adjuvant strategies. Five-year and 10-year RFS were 85.9% and 83.3% for AS; 92.4% and 84.0% for carboplatin one cycle; and 96.7% at both times for carboplatin two cycles.
Conclusion
There were no statistically differences in cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in S1S patients treated with a risk-adapted strategy.
•Immune checkpoint inhibitors emerged as a the predominant 2L treatment, leading to a substantial decrease in the utilization of chemotherapies beyond the 1L.•Despite the introduction of immune ...checkpoint inhibitors, treatment attrition rates remained elevated, with approximately only half of patients undergoing ICIs the post-ICIs era.•When comparing the outcomes of patients treated before and after the introduction of ICIs, we did not observe higher rates of either a 2-year OS or an increase in the number of patients receiving 3L therapies.
Metastatic urothelial carcinoma (mUC) is a lethal disease with limited treatment options. We aimed to compare the treatment patterns and outcomes of patients with mUC who were treated before and after the introduction of immune checkpoint inhibitors (ICIs) at a tertiary hospital in Barcelona.
Single-center retrospective study from 2004 to 2021. Access to ICIs began in December 2014. We analyzed differences in clinical characteristics and survival outcomes, such as overall survival (OS), progression-free survival (PFS), and restricted mean survival time (RMST).
A total of 206 patients were included. The median follow-up was 48.6 months. Ninety and 116 patients were treated during the pre-ICIs and the post-ICIs eras, respectively. We found high treatment attrition rates, with no differences in the number of patients who received second-line (48%) and third-line (26%) therapies between the two eras. In the second-line, ICIs became the predominant therapy (58%), leading to a 30% reduction in the utilisation of platinum-based ChT and non-platinum ChT. Innovative approaches including ICIs in the first-line treatment (18%) and targeted therapies in the third-line setting (34%) were observed. We found no differences in the median OS, 2-year OS, or 24-month RMST between the two periods.
ICIs have emerged as a transformative treatment option, reshaping the treatment landscape. Nevertheless, substantial attrition rates from first-line to subsequent lines of systemic therapies might impede the potential impact of ICIs on long-term survival outcomes across the entire population.
Immune checkpoint inhibitors now serve as a novel treatment option for patients facing metastatic urothelial carcinoma, particularly in the second-line setting, thereby changing the treatment paradigm. Nonetheless, the substantial attrition rates during the transition from the first-line to subsequent lines of systemic therapy may hinder the potential impact of immune checkpoint inhibitors on long-term survival outcomes for the broader population.
We evaluated the prevalence of homologous recombination deficiencies (HRD) to determine the efficacy of different techniques and clinical characteristics of patients.
This retrospective study ...included patients with metastatic prostate cancer who underwent molecular testing at our hospital between 2016 and 2022. We used tumor tissue, ctDNA, and lymphocytes for somatic or germline testing. We analyzed the clinical characteristics and survival outcomes.
144 patients were tested (113 somatic, 21 germline, and 10 both). Technical issues prevented the analysis of 23 prostatic samples (18.7%). 12 (8.3%) patients had HRD. BRCA2 was the most frequent mutation (66.7%). Patients with HRD were younger (57.5 years). Patients with BRCA mutations had poorer survival (31.9 vs 56.3 months, p = 0.048).
In our institution, 8.3% of the patients had HRD. Tumor tissue analysis failed in 18.7% of tests. ctDNA analysis is an alternative detection method. BRCA mutations are correlated with poor prognosis.
Compensation for pain and suffering damages has been a focal point within legal academic debate. The difficulty of placing a monetary value on such damages and the lack of well-defined guidelines ...have been claimed to result in widely varying compensatory awards, making them random and unpredictable. Variability may arise from victim labels depicting who is deserving, and who is not. In this study, regression analysis is employed to assess whether compensation can be predicted, and what role victim labels play in the judicial decision-making. The empirical strategy is informed by notion of the ideal victim. Results show that compensation for pain and suffering damages can be predicted, and that by including victim labels the prediction significantly improves. Although they are not the predominant predictors, victim labels of blamelessness play a role in awarded compensation. The main driver in judges’ decision is the claim put forward by the victim.
